Total ADAR2 Cell-Based Colorimetric ELISA Kit
- 货号:KA3663C
- 应用:ELISA
- 种属:Human;Mouse;Rat
- 基因名称:
- ADARB1
- Human Gene Id:
- 104
- Human Swiss Prot No:
- P78563
- Mouse Swiss Prot No:
- Q91ZS8
- Rat Swiss Prot No:
- P51400
- 储存:
- 2-8°C/6 months
- 其他名称:
- Double-stranded RNA-specific editase 1 (EC 3.5.-.-) (RNA-editing deaminase 1) (RNA-editing enzyme 1) (dsRNA adenosine deaminase)
- 检测方法:
- Colorimetric
- 背景:
- alternative products:Additional isoforms seem to exist,cofactor:Binds 1 inositol hexakisphosphate (IP6) per subunit.,function:Editing of the messenger RNAs for glutamate receptor (GluR) subunits by site-selective adenosine deamination. Edits both the GluR-B Q/R and R/G sites efficiently but converts the adenosine in hotspot1 much less efficiently.,similarity:Contains 1 A to I editase domain.,similarity:Contains 2 DRBM (double-stranded RNA-binding) domains.,
- 功能:
- RNA processing, mRNA processing, RNA modification, mRNA metabolic process, base conversion or substitution editing,
- 细胞定位:
- Nucleus . Nucleus, nucleolus . Shuttles between nucleoli and the nucleoplasm. .; [Isoform 1]: Nucleus . Nucleus, nucleolus .; [Isoform 2]: Nucleus . Nucleus, nucleolus .
- 组织表达:
- Highly expressed in brain and heart and at lower levels in placenta. Fair expression in lung, liver and kidney. Detected in brain, heart, kidney, lung and liver (at protein level). ; [Isoform 5]: Highly expressed in hippocampus and colon. Expressed in pediatric astrocytomas and the protein has a decreased RNA-editing activity. The decrease in RNA editing correlates with the grade of malignancy of the tumors, with the high grade tumors showing lower editing is seen.
- June 19-2018
- WESTERN IMMUNOBLOTTING PROTOCOL
- June 19-2018
- IMMUNOHISTOCHEMISTRY-PARAFFIN PROTOCOL
- June 19-2018
- IMMUNOFLUORESCENCE PROTOCOL
- September 08-2020
- FLOW-CYTOMEYRT-PROTOCOL
- May 20-2022
- Cell-Based ELISA│解您多样本WB检测之困扰
- July 13-2018
- CELL-BASED-ELISA-PROTOCOL-FOR-ACETYL-PROTEIN
- July 13-2018
- CELL-BASED-ELISA-PROTOCOL-FOR-PHOSPHO-PROTEIN
- July 13-2018
- Antibody-FAQs